The FDA Accepts Epizyme Marketing Application
Epizyme (EPZM) reported that the FDA has accepted its marketing application regarding Tazverik. The treatment is being developed for managing patients with relapsed or refractory lymphoma who have received at least two prior lines of systemic therapy. The FDA is scheduled to provide its decision by June 18th. The treatment has been granted Priority Review and the company’s application is deemed to be a supplemental NDA.
Tazverik was approved for epithelioid sarcoma in adults and children 16 or older in January 2020. The drug is